Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Pharma
Aadi lays off 80% of R&D workforce as Fyarro heads to ph. 2 fail
Aadi Bioscience’s Fyarro is on track to fail a phase 2 solid tumor trial, leading the biotech to halt the study and lay off 80% of its R&D workforce.
James Waldron
Aug 21, 2024 4:51am
Gilead's Trodelvy suffers double whammy
May 30, 2024 6:20pm
ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC
May 23, 2024 5:00pm
ASCO: Lilly seeks prostate cancer redemption after Verzenio flop
May 23, 2024 5:00pm
Bristol Myers fails to beat AZ in stage 3 lung cancer
May 13, 2024 10:23am
EyePoint reports Duravyu trial fail, raising questions
May 6, 2024 10:55am
